ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0145

Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Abstract Number: 0146

Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Abstract Number: 0147

Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Abstract Number: 0148

The Incidence and Prevalence of Sarcoidosis in England
Abstract Number: 0149

Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
Abstract Number: 0150

The Characteristics of a Northern Israeli Cohort of Patients with Behcet’s Syndrome
Abstract Number: 0151

Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
Abstract Number: 0152

Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Abstract Number: 0153

Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review
Abstract Number: 0154

Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)
Abstract Number: 0155

Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Abstract Number: 0156

Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Abstract Number: 0157

Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Abstract Number: 0158

Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Abstract Number: 0159

Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].